Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.HPPI · Entity 7783 | Director | December 19, 2017 | February 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date December 19, 2017 · Filed February 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-19 transaction · row 1
1 source rowRow 1 · 2017-12-19 · Purchase · Disposed 600,000 · Balance 0 F1: On December 19, 2017, Stefan Cross sold 600,000 shares of Common Stock to Mayne Pharma Ventures Pty Ltd. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 19, 2017, Stefan Cross sold 600,000 shares of Common Stock to Mayne Pharma Ventures Pty Ltd.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2017 Filed Feb 13, 2018 01:00 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | PurchaseCommon Stock | 600,000 | $162,660.00 | $97,596,000,000.00 |
DisclosureSEC source: 0001144204-18-007442 · tv485758_4.xml · nonDerivative · entry 1 Cross Stefan · CIK 0001611506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 19, 2017, Stefan Cross sold 600,000 shares of Common Stock to Mayne Pharma Ventures Pty Ltd. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007151 · doc4.xml · derivative · entry 4 Cross Stefan · CIK 0001611506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. F3 · derivative.expiration_date: The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007151 · doc4.xml · derivative · entry 3 Cross Stefan · CIK 0001611506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. F2 · derivative.expiration_date: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007151 · doc4.xml · nonDerivative · entry 2 Cross Stefan · CIK 0001611506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | Exercise / conversionCommon Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007151 · doc4.xml · nonDerivative · entry 1 Cross Stefan · CIK 0001611506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The RSUs were issued to the reporting person on July 18, 2014, pursuant to a grant under the issuer's 2014 Equity Incentive Plan, and vested in accordance with their terms. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.